Liao Baolin, Zhang Fuchun, Lin Siwei, He Haolan, Liu Yu, Zhang Jiansheng, Xu Ying, Yi Junqing, Chen Yunqing, Liu Huiyuan, Wang Zhanhui, Cai Weiping
Department of Infectious Disease, Guangzhou No. 8 People's Hospital, Guangzhou Medical University, Guangzhou, China.
Department of Third Internal Medicine, Yuexiu District Traditional Chinese Medicine Hospital, Guangzhou, China.
PLoS One. 2014 Dec 22;9(12):e115888. doi: 10.1371/journal.pone.0115888. eCollection 2014.
The epidemiology of hepatitis D virus (HDV) in China is fairly unknown. The mechanisms whereby HDV leads to accelerated liver disease in hepatitis B virus (HBV)/HDV co-infected patients and the histological characteristics of chronic hepatitis D (CHD) patients need further investigation.
The prevalence of HDV was retrospectively evaluated in all consecutive hospitalized patients with chronic HBV infection from May 2005 to October 2011. HBV/HDV co-infected patients and HBV mono-infected patients were compared clinically and histologically. Significant histological abnormality was defined as significant necroinflammation (grade ≥A2) and/or significant fibrosis (stage ≥ F2).
6.5% of patients (426/6604) tested positive for IgM anti-HDV. HDV was more common in patients over 50 years old than those under 50 (11.7% vs. 5.1%, P<0.001). HBV/HDV co-infected patients had higher frequencies of end-stage liver disease (ESLD) than HBV mono-infected patients, and HDV co-infection was an independent risk factor for ESLD (OR: 1.428, 95%CI: 1.116-1.827; P = 0.005). The HBV DNA levels in the HBV/HDV group were significantly lower than the HBV group in chronic hepatitis patients (median: 6.50 log10copies/mL vs 6.80 log10copies/mL, P = 0.003), but higher than the HBV group in ESLD patients (median: 5.73 log10copies/mL vs 5.16 log10copies/mL, P<0.001). When stratified by alanine aminotransferase (ALT) level, 46.7%, 56.5% and 80.5% of CHD patients had significant necroinflammation and 86.7%, 87.0% and 90.3% had significant fibrosis with ALT 1-2×upper limit normal (ULN), 2-5×ULN and>5×ULN respectively.
The prevalence of HDV is not low in patients with chronic HBV infection. HDV may contribute to progression to ESLD through late-phase HBV DNA reactivation.
中国丁型肝炎病毒(HDV)的流行病学情况尚不清楚。HDV导致乙型肝炎病毒(HBV)/HDV合并感染患者肝病加速进展的机制以及慢性丁型肝炎(CHD)患者的组织学特征需要进一步研究。
对2005年5月至2011年10月期间所有连续住院的慢性HBV感染患者进行HDV流行率的回顾性评估。对HBV/HDV合并感染患者和HBV单一感染患者进行临床和组织学比较。显著的组织学异常定义为显著的坏死性炎症(分级≥A2)和/或显著的纤维化(分期≥F2)。
6.5%的患者(426/6604)抗-HDV IgM检测呈阳性。HDV在50岁以上患者中比50岁以下患者更常见(11.7%对5.1%,P<0.001)。HBV/HDV合并感染患者的终末期肝病(ESLD)发生率高于HBV单一感染患者,HDV合并感染是ESLD的独立危险因素(比值比:1.428,95%置信区间:1.116-1.827;P = 0.005)。慢性肝炎患者中,HBV/HDV组的HBV DNA水平显著低于HBV组(中位数:6.50 log10拷贝/mL对6.80 log10拷贝/mL,P = 0.003),但在ESLD患者中高于HBV组(中位数:5.73 log10拷贝/mL对5.16 log10拷贝/mL,P<0.001)。按丙氨酸氨基转移酶(ALT)水平分层时,CHD患者中,ALT为1-2倍正常上限(ULN)、2-5倍ULN和>5倍ULN时,分别有46.7%、56.5%和80.5%的患者有显著的坏死性炎症,86.7%、87.0%和90.3%的患者有显著的纤维化。
慢性HBV感染患者中HDV的流行率不低。HDV可能通过晚期HBV DNA再激活导致进展为ESLD。